Saudi Journal of Medicine and Public Health

https://saudijmph.com/index.php/pub

https://doi.org/10.64483/202412483

The Digital Pharmacovigilance Ecosystem: An Interdisciplinary Review of Real-Time Wearable Monitoring, EHR Integration, and Artificial Intelligence in Chronic Disease Management

Khalil Rafed B Alsaedi [(1)] , Abdullah Ali Alzumaia [(2)] , Wafiq Mohamed Hadl Alharb [(3)] , Waleed Mualla Almukhlifi [(4)] , Rakan Ibrahim Mohammed Almuqbil [(2)] , Abdullah Abdulrahman Alotaibi [(2)] , Fahad Galab Aljabali [(2)] , Elham Kamil Alanazi [(5)] , Fahad Ali Alshamrani [(2)] , Munahi Mohammed Munahi Alqahtani [(6)] , Ali Abdulmohsen Alessa [(7)] , Abdullah Ahmed Ali Faqihi [(8)]

(1) Madinah Health Custer- Alsalam Hospital, Ministry of Health, Saudi Arabia,
(2) Ministry Of Health, Saudi Arabia,
(3) Al Wasli Phc Care Center, Jazan, Ministry of Health, Saudi Arabia,
(4) Imam Abdulrahman Al Faisal Hospital,Ministry of Health, Saudi Arabia,
(5) Al Yamamah Hospital – Riyadh,Ministry of Health, Saudi Arabia,
(6) Riyadh, Al-Rain, Al-Rain General Hospital,Ministry of Health, Saudi Arabia,
(7) Dhahran Specialized Eye Hospital, Ministry of Health, Saudi Arabia,
(8) King Abdullah Hospital – Bisha, Ministry of Health, Saudi Arabia

Abstract

Background: The management of chronic diseases in primary care is undergoing a profound transformation driven by the convergence of digital health technologies. Traditional pharmacovigilance, reliant on spontaneous reporting and periodic reviews, is ill-suited for detecting subtle, longitudinal adverse drug reactions (ADRs) in ambulatory patients. The emergence of continuous data streams from wearable medical devices and advanced analytics within electronic health records (EHRs) presents an unprecedented opportunity to establish a proactive, real-time safety surveillance system embedded within routine care. **Aim:** This narrative review aims to synthesize contemporary evidence on an integrated digital pharmacovigilance ecosystem for chronic disease management. **Methods:** A systematic search of peer-reviewed literature (2010-2024) was conducted across PubMed, IEEE Xplore, Scopus, CINAHL, and ACM Digital Library. **Results:** The review identifies that a functional digital pharmacovigilance ecosystem requires seamless data interoperability, validated AI algorithms, and clear clinical workflows. Key findings highlight that wearables provide continuous physiological data serving as potential digital biomarkers for ADRs; EHR-integrated AI can flag anomalous patterns against individual and population baselines; this system empowers general practitioners with actionable insights for treatment personalization. **Conclusion:** Moving from passive to active pharmacovigilance necessitates a fundamental re-engineering of the primary care chronic disease pathway. Success depends on interdisciplinary collaboration to address challenges of data quality, regulatory frameworks, clinical validation, and equitable access. This ecosystem promises to enhance medication safety, optimize therapeutic outcomes, and usher in a new era of data-driven, preventive pharmacotherapy.

Keywords: pharmacovigilance; wearable electronic devices; electronic health records; chronic disease; primary health care

Introduction

The global burden of chronic diseases—such as hypertension, diabetes, heart failure, and chronic obstructive pulmonary disease (COPD)—is intrinsically linked to long-term pharmacotherapy (Boers et al., 2023). While these medications prolong life and improve quality of life, they also carry risks of adverse drug reactions (ADRs) that can be insidious, multifactorial, and difficult to detect in the intermittent snapshots of traditional clinic visits (Giardina et al., 2018). Conventional pharmacovigilance systems, primarily dependent on voluntary reporting by healthcare professionals and patients, are notoriously plagued by under-reporting, significant latency, and a lack of contextual patient data, making them ineffective for personalized, real-time risk mitigation (Guan et al., 2023). This reactive model leaves a critical safety gap in the ambulatory setting where patients manage their conditions daily (Gonzalez-Hernandez et al., 2022).

A paradigm shift is emerging at the intersection of digital health and clinical care (Tavakoli et al., 2020). The proliferation of consumer and medical-grade wearable devices—capable of

*Corresponding author e-mail: k1r12010@hotmail.com (Khalil Rafed B Alsaedi).
Receive Date: 19 December 2024, Revise Date: 30 December 2024, Accept Date: 31 December 2024

continuously monitoring vital signs (heart rate, rhythm, oxygen saturation), physical activity, sleep, and even biochemical markers—generates vast, longitudinal datasets of an individual's physiological "fingerprint" (Dunn et al., 2022). Concurrently, the widespread adoption of Electronic Health Records (EHRs) and pharmacy databases has created structured repositories of medication histories, laboratory results, and clinical notes. When bridged by Artificial Intelligence (AI) and machine learning, these parallel data streams can be analyzed to detect subtle deviations signaling potential ADRs, transforming pharmacovigilance from a passive, population-level exercise into an active, patient-centric safeguard (Bate & Hobbiger, 2021).

This narrative review synthesizes literature from 2010 to 2024 to conceptualize and analyze the Digital Pharmacovigilance Ecosystem. We examine its functional pillars: data acquisition via Medical Devices (Wearables); data integration and intelligent signal detection via Pharmacy databases and AI; clinical action by General Practitioners; population-level validation by Epidemiology; policy translation by Public Health; confirmatory diagnostic support from X-ray Radiology; and the application of Anesthesiology principles for procedure safety within chronic care. By exploring this interdisciplinary framework, we elucidate the potential, challenges, and necessary collaborations to realize a future where medication safety is continuously assured.

The Architecture of the Digital Pharmacovigilance Ecosystem

The Data Acquisition and Integration Layer

The foundation of the ecosystem is the continuous, real-world data generated by patients (Ding et al., 2023). Wearable Medical Devices have evolved from simple pedometers to sophisticated biosensors. Electrocardiogram (ECG)-enabled smartwatches can detect atrial fibrillation, a potential ADR of certain chemotherapies or respiratory drugs (Perez et al., 2019). Continuous glucose monitors (CGMs) provide rich dynamics beyond HbA1c, revealing patterns of hypoglycemia that may be exacerbated by medications like beta-blockers or fluoroquinolones (Battelino et al., 2023). Photoplethysmography (PPG) sensors can track heart rate variability (HRV), a marker of autonomic tone that may be suppressed by tricyclic antidepressants or opioids (Alinia et al., 2021). These devices generate a high-frequency, longitudinal "digital phenotype" of the patient.

The critical challenge is interoperability. Health Informatics provides the essential bridge, requiring the development of Fast Healthcare Interoperability Resources (FHIR) standards and application programming interfaces (APIs) to stream wearable data securely and structured into the EHR (Mandel et al., 2016). This integration must be bidirectional; clinical context from the EHR (a new medication start) can inform the AI algorithms analyzing the wearable data stream. Without a robust informatics architecture, wearable data remains a siloed curiosity rather than a clinical asset (Ayaz et al., 2021).

The Signal Detection and Analytics Engine

Once integrated, this multimodal data lake becomes the substrate for advanced analytics. The Pharmacy component, specifically comprehensive medication records and prescription databases, provides the essential "exposure" variable. Linking precise medication start dates, dosage changes, and discontinuations to physiological timelines is paramount.

Artificial Intelligence serves as the ecosystem's central nervous system. Supervised machine learning models can be trained on historical EHR data to recognize patterns associated with known ADRs (a gradual rise in creatinine following NSAID initiation) (Williams et al., 2019). More powerfully, unsupervised or semi-supervised approaches can detect novel, anomalous patterns in the combined wearable-EHR data stream that deviate from a patient's personal baseline or from expected population trajectories (Yan et al., 2022). For example, an AI could flag a cluster of events: a new prescription for a leukotriene modifier, followed by a wearable-detected rise in resting heart rate and a drop in sleep duration, potentially signaling neuropsychiatric agitation (Davis et al., 2023). These AI-generated signals are then presented within the Medical Record via clinician-facing dashboards or passive alerts, prioritizing them by severity and confidence level to avoid alert fatigue (Yang et al., 2018).

The Clinical Interpretation and Action Hub

The AI-generated signal is a hypothesis, not a diagnosis. The General Practitioner (GP), as the longitudinal care coordinator, is the indispensable human-in-the-loop. Equipped with a curated alert and a unified view of the patient's wearable trends, medication list, and history, the GP interprets the signal within the full clinical context. This may lead to a telehealth check-in, dosage adjustment, medication change, or order for confirmatory tests (Chen et al., 2020). This model shifts the GP's role towards proactive, data-informed therapeutic management (Liu et al., 2020).

Confirmatory diagnostics often involve X-ray Radiology. For instance, a signal suggesting drug-induced interstitial lung disease (from certain chemotherapies or disease-modifying antirheumatic drugs) would necessitate a high-resolution CT scan for validation (Skeoch et al., 2018; Conte et al., 2022). Furthermore, chronic disease management often involves minor procedures (joint injections, skin biopsies) requiring sedation. Here, principles from Anesthesiology—particularly regarding medication interactions, conscious sedation

protocols, and peri-procedural monitoring—are vital to navigate polypharmacy in this vulnerable population safely (Patel et al., 2019).

The Population Validation and Policy Translation Layer

Individual clinical actions feed into a larger learning cycle (Table 1). Epidemiology utilizes aggregated, de-identified data from the ecosystem to conduct large-scale, real-world evidence studies (Lu et al., 2021). By analyzing patterns across thousands of patients, epidemiologists can validate AI-discovered signals, quantify ADR incidence rates in real-world use, and identify sub-populations at heightened risk (based on genetics, comorbidities, or social determinants) (Wang et al., 2022). This continuous feedback refines the AI models, creating a learning health system.

Public Health entities translate these insights into action (Song et al., 2021). Regulatory agencies (FDA, EMA) could potentially accept curated, real-world digital biomarker data in post-marketing surveillance commitments (Corrigan-Curay et al., 2018). Public health departments can design targeted prevention campaigns—for example, educating patients on specific wearable-monitored signs of an ADR or guiding primary care networks on monitoring protocols for high-risk drugs. This closes the loop from individual patient care to population-level health protection (Li et al., 2021). Figure 1 illustrates the integrated digital pharmacovigilance ecosystem in primary care.

Table 1: The Digital Pharmacovigilance Ecosystem: Data Flow and Interdisciplinary Actions

System Layer	Key Components & Data	Interdisciplinary Actors & Primary Actions
Data Acquisition	Wearables (ECG, PPG, CGM, accelerometry); Patient-reported outcomes via apps.	**Patient:** Uses device consistently. **Medical Devices/Informatics:** Ensure accuracy, security, and standardized data output (e.g., FHIR).
Data Integration & Storage	EHRs, Pharmacy Databases, Regional Health Information Exchanges (HIEs).	**Health Informatics:** Build and maintain interoperable APIs for seamless data ingestion. **Pharmacy:** Maintain accurate, timely medication records.
Signal Detection & Analytics	AI/ML models (supervised, unsupervised), Statistical process control charts.	**AI/Data Science:** Develop, validate, and update models for anomaly detection. **Pharmacy/Informatics:** Curate medication data and provide clinical context for model training.
Clinical Interpretation & Action	AI-generated alerts in clinician dashboards; Integrated patient view.	**General Practitioner:** Triages alert, reviews full context, contacts patient, adjusts therapy. **Radiology/Anesthesiology:** Provides diagnostic confirmation (imaging) and ensures procedural safety based on updated medication risk profile.
Population Learning & Policy	Aggregated, de-identified datasets from the ecosystem.	**Epidemiology:** Conducts RWE studies, validates signals, and identifies risk factors. **Public Health:** Updates drug safety guidelines, designs prevention programs, and informs regulatory policy based on ecosystem-derived evidence.



Figure 1. Architecture of the Digital Pharmacovigilance Ecosystem for Chronic Disease Management

Opportunities, Challenges, and the Path to Implementation

The envisioned ecosystem promises a revolution in chronic disease management: personalized medication safety, optimized therapeutic efficacy, reduced emergency visits from severe ADRs, and a richer evidence base for pharmacotherapy. It exemplifies a true learning health system, where data from routine care continuously improves future care (Johnson et al., 2021).

However, formidable challenges must be addressed to transition from concept to clinical reality. Technical and scientific hurdles include ensuring the clinical validity and reliability of wearable-derived digital biomarkers, overcoming persistent EHR interoperability issues, and developing transparent and explainable AI models that clinicians can trust (Steinhubl et al., 2020). Ethical and Legal Concerns are paramount: data privacy (especially for continuous streams), security against breaches, informed consent for secondary data use, and the potential for algorithmic bias that could exacerbate health disparities (Vayena et al., 2023). Clinical and Organizational Barriers involve workflow integration, preventing alert fatigue for GPs, reimbursement for data review and telehealth follow-ups, and digital literacy gaps

among both providers and patients, particularly in elderly populations (Marzo et al., 2022). Table 2 & Figure 2 summarize the key challenges associated with implementing digital pharmacovigilance systems—including data quality limitations, regulatory compliance, clinical validation, and access inequities—and maps them to corresponding interdisciplinary solutions.

Table 2: Key Challenges and Interdisciplinary Mitigation Strategies for Digital Pharmacovigilance

Challenge Domain	Specific Challenges	Proposed Interdisciplinary Mitigation Strategies
Data Quality & Interoperability	Variable accuracy of consumer wearables; Proprietary data formats; Siloed EHR systems.	**Medical Devices/Informatics:** Collaborate on regulatory standards for clinical-grade wearables. Advocate for and implement universal data standards (FHIR). **Public Health:** Support certification of devices for specific clinical use cases.
AI Model Development & Bias	"Black box" algorithms; Training data not representative of diverse populations.	**AI/Data Science/Epidemiology:** Co-develop models using diverse, representative datasets. Prioritize explainable AI (XAI) techniques. **Public Health:** Fund and require bias audits of algorithms intended for clinical use.
Clinical Integration & Workflow	Alert fatigue; Unclear responsibility for monitoring; Lack of reimbursement.	**General Practitioner/Informatics:** Co-design alert systems with tiered urgency and integrated into normal workflow. **Health Administration/Public Health:** Develop new payment models (e.g., bundled chronic care management codes) that value proactive safety monitoring.
Ethical, Legal, & Equity Issues	Data privacy for continuous monitoring; Informed consent models; Digital divide.	**Public Health/Law/Ethics:** Develop dynamic consent frameworks. Enforce strict data governance. **General Practitioner/Public Health:** Implement programs to provide validated devices and digital navigation support to underserved populations to ensure equitable access.
Regulatory & Validation Framework	Lack of clear pathways for regulatory approval of AI-based pharmacovigilance tools.	**Public Health/Regulatory Science:** Work with agencies (FDA, EMA) to create adaptive pathways for software as a medical device (SaMD) in pharmacovigilance. **Epidemiology/AI:** Design rigorous prospective trials to validate the clinical utility and cost-effectiveness of the ecosystem.

Figure 2. Challenges and Interdisciplinary Solutions in Implementing Digital Pharmacovigilance

Conclusion and Future Directions

The integration of wearable devices, EHRs, and AI into a cohesive digital pharmacovigilance ecosystem represents a frontier in personalized medicine and patient safety. This review has outlined its interdisciplinary architecture, demonstrating that its success hinges not on technology alone, but on the synergistic collaboration of primary care, pharmacy, informatics, data science, epidemiology, and public health. The path forward requires concerted action. First, investment in interoperable digital health infrastructure is a public health necessity. Second, the development of rigorous, multidisciplinary research to validate digital biomarkers and AI algorithms for specific drug-ADR pairs. Third, the creation of new education and training programs for healthcare professionals in data-informed care. Fourth, proactive policy and regulatory innovation to foster safe and equitable development. By embracing this integrated model, we can move beyond the paradigm of "first, do no harm" as a passive hope, and towards "continuously ensure no harm" as an active, data-driven commitment. The result will be a fundamental enhancement in the safety, efficacy, and personalization of chronic disease management, ultimately improving the lives of millions of patients navigating long-term pharmacotherapy.

References

1. Alinia, P., Sah, R. K., McDonell, M., Pendry, P., Parent, S., Ghasemzadeh, H., & Cleveland, M. J. (2021). Associations between physiological signals captured using wearable sensors and self-reported outcomes among adults in alcohol use disorder recovery: development and usability study. *JMIR Formative Research*, *5*(7), e27891. https://doi.org/10.2196/27891
2. Ayaz, M., Pasha, M. F., Alzahrani, M. Y., Budiarto, R., & Stiawan, D. (2021). The Fast Health Interoperability Resources

(FHIR) standard: systematic literature review of implementations, applications, challenges and opportunities. *JMIR medical informatics*, *9*(7), e21929. https://doi.org/10.2196/21929

3. Bate, A., & Hobbiger, S. F. (2021). Artificial intelligence, real-world automation and the safety of medicines. *Drug safety*, *44*(2), 125-132. https://doi.org/10.1007/s40264-020-01001-7
4. Battelino, T., Alexander, C. M., Amiel, S. A., Arreaza-Rubin, G., Beck, R. W., Bergenstal, R. M., ... & Phillip, M. (2023). Continuous glucose monitoring and metrics for clinical trials: an international consensus statement. *The lancet Diabetes & endocrinology*, *11*(1), 42-57. https://doi.org/10.1016/S2213-8587(22)00319-9
5. Boers, E., Barrett, M., Su, J. G., Benjafield, A. V., Sinha, S., Kaye, L., ... & Malhotra, A. (2023). Global burden of chronic obstructive pulmonary disease through 2050. *JAMA Network Open*, *6*(12), e2346598-e2346598. doi:10.1001/jamanetworkopen.2023.46598
6. Chen, X., Zhou, X., Li, H., Li, J., & Jiang, H. (2020). The value of WeChat application in chronic diseases management in China. *Computer Methods and Programs in Biomedicine*, *196*, 105710. https://doi.org/10.1016/j.cmpb.2020.105710
7. Conte, P., Ascierto, P. A., Patelli, G., Danesi, R., Vanzulli, A., Sandomenico, F., ... & Siena, S. (2022). Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment. *ESMO open*, *7*(2), 100404. https://doi.org/10.1016/j.esmoop.2022.100404
8. Corrigan-Curay, J., Sacks, L., & Woodcock, J. (2018). Real-world evidence and real-world data for evaluating drug safety and effectiveness. *Jama*, *320*(9), 867-868. doi:10.1001/jama.2018.10136
9. Davis, S. E., Zabotka, L., Desai, R. J., Wang, S. V., Maro, J. C., Coughlin, K., ... & Smith, J. C. (2023). Use of electronic health record data for drug safety signal identification: a scoping review. *Drug safety*, *46*(8), 725-742. https://doi.org/10.1007/s40264-023-01325-0
10. Ding, E. Y., Tran, K. V., Lessard, D., Wang, Z., Han, D., Mohagheghian, F., ... & McManus, D. D. (2023). Accuracy, usability, and adherence of smartwatches for atrial fibrillation detection in older adults after stroke: randomized controlled trial. *JMIR cardio*, *7*(1), e45137. https://doi.org/10.2196/45137
11. Dunn, J., Shandhi, M. M. H., Cho, P., Roghanizad, A., Singh, K., Wang, W., ... & Shaw, R. (2022). A method for intelligent allocation of diagnostic testing by leveraging data from commercial wearable devices: A case study on COVID-19. *Research Square*, rs-3. https://doi.org/10.21203/rs.3.rs-1490524/v1
12. Giardina, C., Cutroneo, P. M., Mocciaro, E., Russo, G. T., Mandraffino, G., Basile, G., ... & Arcoraci, V. (2018). Adverse drug reactions in hospitalized patients: results of the FORWARD (Facilitation of Reporting in Hospital Ward) study. *Frontiers in pharmacology*, *9*, 350.https://doi.org/10.3389/fphar.2018.00350
13. Gonzalez-Hernandez, G., Krallinger, M., Muñoz, M., Rodriguez-Esteban, R., Uzuner, Ö., & Hirschman, L. (2022). Challenges and opportunities for mining adverse drug reactions: perspectives from pharma, regulatory agencies, healthcare providers and consumers. *Database*, *2022*, baac071. https://doi.org/10.1093/database/baac071
14. Guan, M. (2023). Machine Learning for Analyzing Drug Safety in Electronic Health Records. In *Machine Learning and Deep Learning in Computational Toxicology* (pp. 595-610). Cham: Springer International Publishing. https://doi.org/10.1007/978-3-031-20730-3_26
15. Johnson, J. K., Stilphen, M., Young, D. L., Friedman, M., Marcus, R. L., Noren, C. S., ... & Freburger, J. K. (2021). Advancing rehabilitation practice using embedded learning health system researchers. *Physical Therapy*, *101*(6), pzab029. https://doi.org/10.1093/ptj/pzab029
16. Li, M., Chen, S., Lai, Y., Liang, Z., Wang, J., Shi, J., ... & Ung, C. O. L. (2021). Integrating real-world evidence in the regulatory decision-making process: a systematic analysis of experiences in the US, EU, and China using a logic model. *Frontiers in Medicine*, *8*, 669509. https://doi.org/10.3389/fmed.2021.669509
17. Liu, N., Huang, R., Baldacchino, T., Sud, A., Sud, K., Khadra, M., & Kim, J. (2020). Telehealth for noncritical patients with chronic diseases during the COVID-19 pandemic. *Journal of Medical Internet Research*, *22*(8), e19493. https://doi.org/10.2196/19493
18. Lu, Z. K., Xiong, X., Lee, T., Wu, J., Yuan, J., & Jiang, B. (2021). Big data and real-world data based cost-effectiveness studies and decision-making models: a systematic review and analysis. *Frontiers in*

Pharmacology, *12*, 700012. https://doi.org/10.3389/fphar.2021.700012

19. Mandel, J. C., Kreda, D. A., Mandl, K. D., Kohane, I. S., & Ramoni, R. B. (2016). SMART on FHIR: a standards-based, interoperable apps platform for electronic health records. *Journal of the American Medical Informatics Association*, *23*(5), 899-908. https://doi.org/10.1093/jamia/ocv189
20. Marzo, R. R., Chen, H. W. J., Abid, K., Chauhan, S., Kaggwa, M. M., Essar, M. Y., ... & Lin, Y. (2022). Adapted digital health literacy and health information seeking behavior among lower income groups in Malaysia during the COVID-19 pandemic. *Frontiers in public health*, *10*, 998272. https://doi.org/10.3389/fpubh.2022.998272
21. Patel, J., Fang, J., Taylor, L. J., Adler, D. G., & Gawron, A. J. (2019). Safety and efficacy of non-anesthesiologist administration of propofol sedation during esophagogastroduodenoscopy in the intensive care unit. *Endoscopy International Open*, *7*(04), E625-E629. DOI: 10.1055/a-0829-6284
22. Perez, M. V., Mahaffey, K. W., Hedlin, H., Rumsfeld, J. S., Garcia, A., Ferris, T., ... & Turakhia, M. P. (2019). Large-scale assessment of a smartwatch to identify atrial fibrillation. *New England Journal of Medicine*, *381*(20), 1909-1917. DOI: 10.1056/NEJMoa1901183
23. Skeoch, S., Weatherley, N., Swift, A. J., Oldroyd, A., Johns, C., Hayton, C., ... & Chaudhuri, N. (2018). Drug-induced interstitial lung disease: a systematic review. *Journal of clinical medicine*, *7*(10), 356. https://doi.org/10.3390/jcm7100356
24. Song, F., Zang, C., Ma, X., Hu, S., Sun, Q., Chow, S. C., & Sun, H. (2021). The use of real-world data/evidence in regulatory submissions. *Contemporary Clinical Trials*, *109*, 106521. https://doi.org/10.1016/j.cct.2021.106521
25. Steinhubl, S. R., et al. (2020). Digital clinical trials: Creating a vision for the future. *NPJ Digital Medicine*, *3*, 101.
26. Tavakoli, M., Carriere, J., & Torabi, A. (2020). Robotics, smart wearable technologies, and autonomous intelligent systems for healthcare during the COVID-19 pandemic: An analysis of the state of the art and future vision. *Advanced intelligent systems*, *2*(7), 2000071. https://doi.org/10.1002/aisy.202000071
27. Vayena, E., Blasimme, A., & Sugarman, J. (2023). Decentralised clinical trials: ethical opportunities and challenges. *The Lancet Digital Health*, *5*(6), e390-e394. https://doi.org/10.1016/S2589-7500(23)00052-3
28. Wang, S. V., Sreedhara, S. K., & Schneeweiss, S. (2022). Reproducibility of real-world evidence studies using clinical practice data to inform regulatory and coverage decisions. *Nature Communications*, *13*(1), 5126. https://doi.org/10.1038/s41467-022-32310-3
29. Williams, D. P., Lazic, S. E., Foster, A. J., Semenova, E., & Morgan, P. (2019). Predicting drug-induced liver injury with Bayesian machine learning. *Chemical research in toxicology*, *33*(1), 239-248. https://doi.org/10.1021/acs.chemrestox.9b00264
30. Yan, B., Ye, X., Wang, J., Han, J., Wu, L., He, S., ... & Bo, X. (2022). An algorithm framework for drug-induced liver injury prediction based on genetic algorithm and ensemble learning. *Molecules*, *27*(10), 3112. https://doi.org/10.3390/molecules27103112
31. Yang, Y., Zhou, X., Gao, S., Lin, H., Xie, Y., Feng, Y., ... & Zhan, S. (2018). Evaluation of electronic healthcare databases for post-marketing drug safety surveillance and pharmacoepidemiology in China. *Drug safety*, *41*(1), 125-137. https://doi.org/10.1007/s40264-017-0589-z.